Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Congestive Heart Failure (Heart Failure) – Pipeline Review, H2 2017’, provides an overview of the Congestive Heart Failure (Heart Failure) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure)

The report reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Congestive Heart Failure (Heart Failure) therapeutics and enlists all their major and minor projects

The report assesses Congestive Heart Failure (Heart Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Congestive Heart Failure (Heart Failure)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acorda Therapeutics Inc

Amgen Inc

AnGes MG Inc

Araim Pharmaceuticals Inc

Arbor Pharmaceuticals LLC

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athersys Inc

Bayer AG

BEAT BioTherapeutics Corp

BioCardia Inc

BlueRock Therapeutics

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

C&C BioPharma LLC

Capricor Therapeutics Inc

Celixir Ltd

Celyad SA

Egalet Corp

F. Hoffmann-La Roche Ltd

FibroGen Inc

Galenica Ltd

GlaxoSmithKline Plc

Heart Metabolics Ltd

Hemostemix Ltd

Immunwork Inc

Innopharmax Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juventas Therapeutics Inc

La Jolla Pharmaceutical Company

Lead Discovery Center GmbH

Lee's Pharmaceutical Holdings Ltd

Les Laboratoires Servier SAS

Lonestar Heart Inc

Madeleine Pharmaceuticals Inc

Merck & Co Inc

Mesoblast Ltd

MorphoSys AG

N-Gene Research Laboratories Inc

NanoCor Therapeutics Inc

Neurocrine Biosciences Inc

Novartis AG

Nuo Therapeutics Inc

Orion Oyj

Palatin Technologies Inc

Paradigm Biopharmaceuticals Ltd

PharmaIN Corp

PhaseBio Pharmaceuticals Inc

Quantum Genomics SA

Recardio GmbH

Renova Therapeutics Inc

Sarfez Pharmaceuticals Inc

Savara Inc

scPharmaceuticals Inc

Stealth BioTherapeutics Inc

Stemedica Cell Technologies Inc

Takeda Pharmaceutical Company Ltd

Theravance Biopharma Inc

TiGenix NV

Torrent Pharmaceuticals Ltd

Trevena Inc

U.S. Stem Cell Inc

Vicore Pharma AB

XyloCor Therapeutics Inc

Zensun (Shanghai) Sci & Tech Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Congestive Heart Failure (Heart Failure) - Overview 6

Congestive Heart Failure (Heart Failure) - Therapeutics Development 7

Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 26

Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 40

Congestive Heart Failure (Heart Failure) - Drug Profiles 75

Congestive Heart Failure (Heart Failure) - Dormant Projects 360

Congestive Heart Failure (Heart Failure) - Discontinued Products 366

Congestive Heart Failure (Heart Failure) - Product Development Milestones 368

Appendix 380

List of Tables

List of Tables

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Acorda Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Amgen Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by AnGes MG Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Araim Pharmaceuticals Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Arbor Pharmaceuticals LLC, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Ascendia Pharmaceuticals LLC, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by AstraZeneca Plc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Athersys Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Bayer AG, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by BEAT BioTherapeutics Corp, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by BioCardia Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by BlueRock Therapeutics, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Boehringer Ingelheim GmbH, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Bristol-Myers Squibb Company, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by C&C BioPharma LLC, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Capricor Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Celixir Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Celyad SA, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Egalet Corp, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by FibroGen Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Galenica Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by GlaxoSmithKline Plc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Heart Metabolics Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Hemostemix Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Immunwork Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Innopharmax Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Johnson & Johnson, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Juventas Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by La Jolla Pharmaceutical Company, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lead Discovery Center GmbH, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Les Laboratoires Servier SAS, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Lonestar Heart Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Madeleine Pharmaceuticals Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Merck & Co Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Mesoblast Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by MorphoSys AG, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by N-Gene Research Laboratories Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by NanoCor Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Neurocrine Biosciences Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Novartis AG, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Nuo Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Orion Oyj, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Palatin Technologies Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by PharmaIN Corp, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by PhaseBio Pharmaceuticals Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Quantum Genomics SA, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Recardio GmbH, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Renova Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Savara Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by scPharmaceuticals Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Stealth BioTherapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Stemedica Cell Technologies Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Theravance Biopharma Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by TiGenix NV, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Torrent Pharmaceuticals Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Trevena Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by U.S. Stem Cell Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Vicore Pharma AB, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by XyloCor Therapeutics Inc, H2 2017

Congestive Heart Failure (Heart Failure) – Pipeline by Zensun (Shanghai) Sci & Tech Co Ltd, H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017 (Contd..4), H2 2017

Congestive Heart Failure (Heart Failure) – Dormant Projects, H2 2017 (Contd..5), H2 2017

Congestive Heart Failure (Heart Failure) – Discontinued Products, H2 2017

Congestive Heart Failure (Heart Failure) – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Congestive Heart Failure (Heart Failure), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports